<a href="https://laohu8.com/S/IMDX">Insight Molecular Diagnostics Inc.</a> reports $260,000 Q3 2025 revenue from laboratory services
Insight Molecular Diagnostics Inc. reported revenues of $0.26 million in Q3 2025, derived from laboratory services performed at its Nashville clinical laboratory. The company remains pre-revenue in relation to kitted product sales, with no kitted product revenue recognized in the quarter. Gross profit was $0.14 million, representing a 53.5% gross margin. Research and development expenses rose 18% sequentially to $3.9 million, while sales and marketing expenses declined 5% to $1.4 million. General and administrative expenses decreased 4% to $2.5 million. The company reported a net loss of $10.9 million, or ($0.34) per share. Cash, cash equivalents, and restricted cash totaled $20.2 million at quarter end. Outgoing cash flow from operations was $4.6 million, with capital expenditures of $1.1 million. The company continues to invest in FDA-compliant product development and anticipates increased expenses in Q4 2025 related to its FDA program.
Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Insight Molecular Diagnostics Inc. published the original content used to generate this news brief via EDGAR, the Electronic Data Gathering, Analysis, and Retrieval system operated by the U.S. Securities and Exchange Commission (Ref. ID: 0001493152-25-021513), on November 10, 2025, and is solely responsible for the information contained therein.
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.